CHIR99021 HCl|cas 1797989-42-4|DC Chemicals

Cas No.:	1797989-42-4
Chemical Name:	Laduviglusib monohydrochloride
Synonyms:	CHIR-99021 Hydrochloride;C22H18Cl2N8.HCl;BCP26126;s2924;SW219488-1;X7424;CHIR-99021 HCl;CHIR-99021 monohydrochloride;Laduviglusib monohydrochloride;CHIR99021 HCl;AKOS032945129;Laduviglusib (monohydrochloride);6-((2-((4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile hydrochloride;BC162488;CHIR-99021 (CT99021) HCl;6-((2-((4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile monohydrochloride;6-[(2-{[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile hydrochloride;CS-5969;CHIR-911 hydrochloride;1797989-42-4;6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile;hydrochloride;CHIR-99021 Hydrochloride; CHIR 911 Hydrochloride; CT 99021 Hydrochloride; CHIR99021;DA-51835;CCG-265009;CHIR-99021 HCl?;SCHEMBL17165152;HY-10182A;CHIR-99021 (monohydrochloride);UNII-5AW8G37ZX5;3-Pyridinecarbonitrile, 6-((2-((4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl)amino)ethyl)amino)-, hydrochloride (1:1);Laduviglusib hydrochloride;AS-19380;AC-33146;CHIR 99021 hydrochloride;AKOS037643639;5AW8G37ZX5;CT99021 monohydrochloride
SMILES:	ClC1C=C(C=CC=1C1C(=CN=C(N=1)NCCNC1C=CC(C#N)=CN=1)C1=NC=C(C)N1)Cl.Cl
Formula:	C₂₂H₁₉Cl₃N₈
M.Wt:	501.7989
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	CHIR-99021 monohydrochloride is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.
In Vivo:	In ZDF rats, a single oral dose of CHIR 99021 (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. CHIR99021 (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). CHIR99021 treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. CHIR99021 treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[4].
In Vitro:	CHIR 99021inhibits human GSK-3β with Ki values of 9.8 nM[1]. CHIR 99021 is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that CHIR 99021 specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[2]. In the presence of CHIR-99021 the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM CHIR-99021 with an IC50 of 4.9 μM[3].

Cat. No.	Product name	Field of application
DC71176	TC-G 24	TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM.
DC7004	AR-A014418(GSK3β Inhibitor VIII)	AR-A014418 is a selective and effective GSK3β inhibitor with an IC 50 value of 104 +/- 27 nM; no significant inhibition on 26 other kinases.
DC1063	TWS119	TWS119 is a GSK-3β inhibitor with IC50 of 30 nM.
DC7680	IM-12	The GSK3β Inhibitor XIX, IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.
DC4227	SB216763	SB 216763 is a potent and selective cell permeable ATP-competitive inhibitor of GSK3α with an IC50 value of 34 nM (similar potency for GSK3β).
DC9726	CP21 (CP21R7)	CP21R7 is a potent and selective GSK-3β inhibitor.
DC1023	CHIR-99021 (CT99021)	CHIR-99021 is a glycogen synthase kinase 3 beta inhibitor that has antiproliferative activity in vitro and in vivo.
DC9703	CHIR-99021 HCl	CHIR-99021 HCl is a potent and selective inhibitor of glycogen synthase kinase 3 beta (GSK-3β), a key enzyme involved in regulating various cellular processes, including metabolism, cell proliferation, and differentiation. By inhibiting GSK-3β, CHIR-99021 HCl modulates downstream signaling pathways, particularly the Wnt/β-catenin pathway, leading to significant biological effects both in vitro and in vivo.
DC7384	CHIR-98014	CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
DC7663	BIO	BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5, also a pan-JAKinhibitor.

CHIR-99021 HCl